

## Optical Imaging Agents Publications

### Tracer 653 Probe

- Smith BA, Xie BW, Beek E, Que I, Blankevoort V, Xiao S, Cole E, Hoehn M, Kaijzel E, Lowik C, Smith BD. 2012. *Multicolor Fluorescence Imaging of Traumatic Brain Injury in a Cryolesion Mouse Model*. **ACS Chem. Neuroscience** 3, 530-537.
- Cole EL, Arunkumar E, Xiao S, Smith BA, Smith BD. 2012. *Water-soluble, deep-red fluorescent squaraine rotaxanes*. **Org. Biomol. Chem.** 10(30): 5769-5773.

### CyAL-5 2-Deoxyglucose Probe

- Hicks RJ, Wahl RL. 2010. *PET diagnosis and response monitoring in oncology*, **Mol. Imaging**, Principles and Practice, p875-895.
- Mankoff DA. 2010. *PET imaging in cancer clinical trials*, **Mol. Imaging**, Principles and Practice, p1179-1191.
- Kovar JL, Volcheck W, Olive DM, Simpson MA. 2007. *IRDye 800CW 2-deoxyglucose, a near infrared metabolic optical imaging agent?* Abstract #5527, Poster presentation, **AACR Annual Meeting**.
- Lloyd PG, Hardin CD, Sturek M. 1999. *Examining glucose transport in single vascular smooth muscle cells with a fluorescent glucose analog*. **Physiol. Res.** 48: 401-410

### CyAL-5-cyclic RGD Probe

- Desgrosellier JS, Cheresh DA. 2010. *Integrins in cancer: biological implications and therapeutic opportunities*. **Nat Rev Cancer**.10:9-22.
- Pfaff M, Tangemann K, Müller B et al. 1994. Selective recognition of cyclic RGD peptides of NMR defined conformation by  $\alpha 11\beta 3$ ,  $\alpha v\beta 3$ , and  $\alpha 5\beta 1$  integrins. **J Biol Chem**. 269:20233-8.
- Gottschalk KE, Kessler H. 2002. *The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction*. **Angew Chem Int Ed Engl**. 41:3767-74
- Boturyn D, Dumy P. 2001. *A convenient access to  $\alpha v\beta 3/\alpha v\beta 5$  integrin ligand conjugates: regioselective solid-phase functionalization of an RGD based peptide*. **Tetrahedron Lett**. 42:2787-9